RARE
Ultragenyx Pharmaceutical Inc.
$33.82
-0.79 (-2.28%)
At close · Jul 10
Market Cap
$3.33B
Shares
98,489,224
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$33.82
Open$34.61
Day$32.72–34.81
52W$18.29–39.89
Avg vol 30d2.6M
Short int16.2M · 16.5% float · 3.6d
Short vol67%
Last earningsMay 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Aug 4, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+25%
above
Price vs 50-day avg
+28%
above
RSI (14)
69
neutral
MACD trend
Positive
52-week position
72%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+47%
trailing
6-month return
+44%
trailing
YTD return
+47%
this year
Relative strength
+35%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $26 › 200d $27 — 200d above 50d
Institutional flow
Distributing
10 of 294 funds reported for Jun 30 · net -2.2M sh shares · +1 new
Insider flow
Distributing
Net -$430.1K over 90 days · 100% sells
Short interest
Rising
16.47% of float · ▲ +13.3% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
294 holders — mid 3-yr range
Squeeze score
75
high risk · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
EPS growth
+7%
Y/Y
Free cash flow
$-472.0M
Balance sheet
$421.0M
net cash
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
4.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 5, 2026
Total revenue
· full year 2026
Raised
$730M – $760M
prior FY $673M
midpoint +10.7% Y/Y
Crysvita revenue
· full year 2026
Lowered
$500M – $520M
prior FY $673M
midpoint −24.2% Y/Y
Dojolvi revenue
· full year 2026
Lowered
$100M – $110M
prior FY $673M
midpoint −84.4% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+25%
Bullish
Price vs 50-day avg
+28%
Bullish
RSI (14)
69
Neutral
MACD trend
Positive
Bullish
52-week position
72%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $26 › 200d $27 — 200d above 50d
Institutional flow
Distributing
10 of 294 funds reported for Jun 30 · net -2.2M sh shares · +1 new
Insider flow
Distributing
Net -$430.1K over 90 days · 100% sells
Short interest
Rising
16.47% of float · ▲ +13.3% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
294 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $18
Now $34 · 72%
52-wk high $40
vs 200-day avg +25%
vs 50-day avg +28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| patients in long-term extension study (GTX-102) | 66 | Q1 FY2026 call | — |
| patients on commercial CRISPR therapy in Latin America | 950 | Q1 FY2026 call | — |
| patients on reimbursed therapy (Dojolvi) in North America | 675 | Q1 FY2026 call | — |
| patients on therapy in Europe (Dojolvi, named patient or early access) | 300 | Q1 FY2026 call | — |
| patients receiving Evkesa across 18 countries | 370 | Q1 FY2026 call | — |
| patients treated with GTX-102 in Phase I-II program | 74 | Q1 FY2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RARE
this stock
Ultragenyx Pharmaceutical Inc.
|
$3.33B | +47.0% | +20.2% | — | 16.5% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RARE | +1.1% | +47.2% | +43.9% | +1.3% | +47.0% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -0.3% | +43.2% | +34.9% | +0.2% | +36.3% |
Key facts
CIK
1515673
CUSIP
90400D108
13F (30d)
11 filings
10 filers
Visit website
Investor relations